Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes by Vlaar, Annemarie MM et al.
BioMed  Central
Page 1 of 13
(page number not for citation purposes)
BMC Neurology
Open Access Research article
Meta-analysis of the literature on diagnostic accuracy of SPECT in 
parkinsonian syndromes
Annemarie MM Vlaar1, Marinus JPG van Kroonenburgh2, Alfons GH Kessels3 
and Wim EJ Weber*1
Address: 1Department of Neurology, University Hospital Maastricht, The Netherlands, 2Department of Nuclear Medicine, University Hospital 
Maastricht, The Netherlands and 3Department of Clinical Epidemiology and Technology Assessment, University Hospital Maastricht, The 
Netherlands
Email: Annemarie MM Vlaar - a.vlaar@neurologie.azm.nl; Marinus JPG van Kroonenburgh - mvkr@lnug.azm.nl; 
Alfons GH Kessels - akes@kemta.azm.nl; Wim EJ Weber* - wweb@neurologie.azm.nl
* Corresponding author    
Abstract
Background: Parkinson's disease (PD) is the second most common neurodegenerative disorder.
One of the most widely used techniques to diagnose PD is a Single Photon Emission Computer
Tomography (SPECT) scan to visualise the integrity of the dopaminergic pathways in the brain.
Despite this there remains some discussion on the value of SPECT in the differential diagnosis of
PD. We did a meta-analysis of all the existing literature on the diagnostic accuracy of both pre- and
post-synaptic SPECT imaging in the differential diagnosis of PD.
Methods: Relevant studies were searched in Medline, EMBASE and Cochrane databases with
back-searching of their reference lists. We limited our analysis to studies with a clinically relevant
methodology: i.e. when they assessed the ability of the SPECT to provide 1. diagnosis of PD in an
early phase vs. normalcy; 2 diagnostic differentiation between PD and essential tremor (ET); 3.
distinguishing between PD and vascular parkinsonism (VP); 4. delineation of PD from atypical
parkinsonian syndromes (APS). Gold standard was, dependent on the study type, clinical
examination at initial visit or follow-up, and/or response to dopaminergic agents.
Results: The search gave 185 hits, of which we deemed 32 suitable for our analysis. From these
we recalculated the diagnostic odds ratio of SPECT for the clinical questions above. The pooled
odds ratio (with 95%CI) for presynaptic SPECT scan's ability to distinguish between early PD and
normalcy was 60 (13 – 277). For the ability to differentiate between PD and ET this ratio was 210
(79–562). The ratio for presynaptic SPECT's ability to delineate PD from VP was 105 (32 – 348).
The mean odds ratio for the presynaptic SPECT scans to differentiate between PD and the two
APS was 2 (1 – 4), and for the postsynaptic SPECT imaging this was 19 (9–36).
Conclusion: SPECT with presynaptic radiotracers is relatively accurate to differentiate patients
with PD in an early phase from normalcy, patients with PD from those with ET, and PD from VP.
The accuracy of SPECT with both presynaptic and postsynaptic tracers to differentiate between PD 
and APS is relatively low.
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Background
Parkinson's disease (PD) is the second most common
neurodegenerative disorder with a life-time risk of 2 per-
cent in males and 1.3 percent in females [1]. In most cases
the diagnosis of PD is straightforward when cardinal clin-
ical signs and symptoms as bradykinesia, rigidity, and
resting tremor are present [2]. However, these main fea-
tures of PD are shared, at least in part, by essential tremor
(ET), multisystem atrophy (MSA), progressive supranu-
clear palsy (PSP), vascular parkinsonism (VP), dementia
with Lewy bodies, corticobasal degeneration, Alzheimer's
disease, and drug-induced parkinsonism. Besides deline-
ating PD from the above parkinsonian disorders, distin-
guishing PD from normality can also be difficult,
especially in early stage of the disease [3].
The gold standard for the diagnosis of PD is post-mortem
neuropathological examination [2,4]. Neuropathological
studies show that even at end-stage disease the clinical
diagnostic accuracy for PD varies between 75–90%, with
MSA and PSP accounting for most false positives [2,5-7].
Diagnostic accuracy is certainly less than 90% in earlier
disease, as Litvan et al. found that the median sensitivity
for the diagnosis of PD increased from 73% at the first
visit to 80% to the last visit after a mean follow-up of 9
years, and the median positive predictive value increased
from 46 to 64% [8].
A reliable test to diagnose PD is important for two rea-
sons. Prognosis and management of PD and other parkin-
sonian disorders differ considerably [9], and an objective
disease marker would facilitate the development of neuro-
protective therapies [10]. Several procedures have been
proposed to diagnose PD: functional imaging with Posi-
tron Emission Tomography (PET) or Single Photon Emis-
sion Computer Tomography (SPECT), transcranial
sonography, olfactory- and neuropsychological tests,
biomarkers and DNA tests [11-14].
At the moment neuro-imaging techniques like PET and
SPECT are the most widely used diagnostic tools [9]. PET
is at least as reliable as SPECT, but its use in routine clini-
cal practice is limited by high costs and a relative short
half-life of its radioactive tracers [15-18]. Different radi-
otracers can be used to visualise the nigrostriatal system.
Presynaptic tracers are used to visualize the dopamine
transporter, and postsynaptic radiotracers to assess
dopamine receptor density. Examples of presynaptic radi-
otracers are Iodine-123-beta-CIT, Iodine-123-Ioflupane
(FP-CIT), Iodine-123-IPT and 99mCT-TRODAT-1. Exam-
ples of postsynaptic tracers are Iodine-123-iodobenza-
mide and Iodine-123-Iodobenzofuran [19].
Despite its widespread use, there is no consensus about
the value of SPECT in the differential diagnosis of PD.
First, comparisons between this functional dopaminergic
imaging and the ultimate gold standard, autopsy-proven
PD, are almost non-existent [20,21]. Second, using a sur-
rogate gold standard in the form of a long-term clinical
follow-up, the ability of SPECT to discriminate PD from
normality and/or other parkinsonian disorders and to dis-
tinguish one of the atypical parkinsonian syndromes from
the other varies greatly among different studies. Compar-
ing these studies is difficult, as they use different radiotrac-
ers and SPECT techniques, and, more importantly,
involve different patient populations. A major issue here
is that many studies use clearly-defined later-stage
patients that are obviously not representative for the diag-
nostic problem that one wants to solve with a SPECT.
With this perspective of clinical relevance we did a meta-
analysis of all the existing literature on the diagnostic
accuracy of both pre- and post-synaptic SPECT in the dif-
ferential diagnosis of PD. We defined studies as clinically
relevant when they dealt with the ability of the SPECT to
identify PD in patients with diagnostic uncertainty, to
delineate PD from the other parkinsonian disorders and
ET, and to provide an early diagnosis of PD in patients
with little signs and symptoms.
Methods
Data sources
Meta-analysis was done according to current methodolog-
ical recommendations [22-24]. We searched MEDLINE
using the following terms: PD, parkinsonian, MSA, PSP,
VP and ET. We searched for MeSH terms and free text
words. All in combination with SPECT and clinical trial.
No beginning data limit was used. The search was updated
until 9 January 2006. Only English-, Dutch- and German
language studies were considered, because the investiga-
tors were familiar with these languages. The bibliogra-
phies of selected articles were screened for potentially
suitable references which were then retrieved. We also
searched the EMBASE and Cochrane database (Wiley
InterScience) using the same search strategy.
Study selection
Two investigators (AV, WW) screened the full text of
potential relevant articles using the inclusion criteria. For
this we use a standard form combined with a modified
QUADAS score, see table 1 (form available upon request)
[25]. In all cases the investigators reached consensus.
Studies were selected if the subject of the study was in one
of the following three areas:
1. Patients who underwent SPECT because of diagnostic
uncertainty.BMC Neurology 2007, 7:27 http://www.biomedcentral.com/1471-2377/7/27
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2. Cross-sectional study of already diagnosed patient cate-
gories, in which SPECT was tested as a means to differen-
tiate between various parkinsonian syndromes.
3. Cross-sectional studies with patients with known PD in
an early stage (Hoehn & Yahr stage 2 or less) vs. normal
healthy controls, in which SPECT was tested as a means to
provide an early diagnosis.
Exclusion criteria
The following exclusion criteria were used: 1) whole arti-
cle not available, 2) language different from English, Ger-
man or Dutch, 3) studies including only advanced PD
patients vs. healthy controls, and studies with other main
categories, e.g. dementia, 4) study population with less
than 10 patients, 5) if the numbers of true positives, false
negatives, true negatives and false positives with a cut-off
point of 2 standard deviations (SD) from the mean of the
control group were not available or could not be derived
the study was excluded.
When the study included more than 85 patients we con-
tacted the corresponding author to ask for the raw data
(see below).
We chose this approach, because we expected a substan-
tial cut-off point effect in the included studies. We did not
want to be dependent upon the assumption that the diag-
nostic odds ratio's in our study would not be affected by
differences in the individual cut-off points. To reduce het-
erogeneity we decided to choose one common cut-off
point for all studies. We took a cut-off point of two stand-
ard deviations (SD) after consulting with nuclear imaging
experts in our hospital and the University Hospital of
Amsterdam. Both departments use a cut-off point of 2
SD's below healthy controls. So we recalculated all results
from all studies using the individual data from tables and
figures in the published paper, using this new cut-off
point. If recalculation was not possible (when data for
individual patients were not traceable from the manu-
script), we excluded the study. This exclusion leads to bias,
of course. We feel, however, that, as these studies did not
adhere to recommended guidelines by not providing the
raw scan results to allow the construction of the diagnostic
2 × 2 table, we did not exclude the methodologically best
studies [24].
Data extraction and analyses
Sensitivity, specificity and the odds ratio was calculated
for each study separately, and the pooled odds ratio's
(OR) for all studies together. Although we tried to reduce
heterogeneity by recalculating study results using one
common cut-off point, we still expected a threshold effect,
because of differences in patients, SPECT machinery, radi-
otracers etc. Therefore, according to recommendations by
Deekes and Egger we used diagnostic OR's [26].
For studies with zeroes in one or more cells 0.5 was added
to all four cells of the 2 × 2 table. Trials with a sensitivity
of 100% and a specificity of 0% were not excluded, how-
ever the pooled OR's were also calculated without such
studies (See # in Figure 4, 5 and 6).
All results were put in software SPSS 11.0 for Windows
and later converted to Stata/SE9.
The metan and metareg commands were built in Stata/
SE9. Because of the heterogeneity of the selected studies
we used a random model to calculate the diagnostic odds
ratios. Heterogeneity was calculated with the I 2 [27].
Results
Literature search
The search on Medline (SPECT & clinical trial) gave 1503
hits. When we added all parkinsonian disorders we lim-
ited the Medline search to 56 relevant hits.
In the Cochrane database we found 26 hits and in Embase
45 hits, but no additional clinical studies above the ones
found in Medline. With cross-reference searching we
found an additional 128 relevant trials (See additional file
1). Together with our own retrospective study of 248
patients with unclear parkinsonism who underwent
SPECT in the period 2001 to 2006, this resulted in 185
possibly relevant studies [28].
Of these 185 we excluded 153 studies (See additional file
2). Seven were excluded because of the language criteria
and 85 articles were excluded as they did not deal with
one of our three designated areas of clinical relevancy:
most of them were about techniques, dementia or drug
efficacy. We excluded an additional 61, because the abso-
lute numbers with a cut-off point of 2 standard deviations
below the control group were not available or could not
be derived. We mailed the authors of the four studies with
more than 85 patients, to ask for missing data [29-32],
and received a response from 1 [30]. We wanted to
acquire raw data from relatively large studies that would
have a substantial impact on our meta-analysis; there were
4 large studies with more than 85 patients, the rest
involved smaller numbers in the 20–35 range. We thus
sought to contact the authors of these 4 studies, as we felt
that studies with less than 85 subjects would have a very
limited impact on the overall scores.
Of the 32 trials left (See additional file 3) 7 dealt with
diagnostic uncertainty including a clinical follow-up as
surrogate gold standard, 20 studies were cross-sectional
including subjects with known parkinsonian disorders,
and 6 studies involved patients with early PD. One clinical
study fitted as well in the early PD groups as in the study
group of known parkinsonian disorders [33]. Of the 7 fol-
low-up studies, 5 were prospective. Of these prospective
analyses, 2 included untreated new patients with parkin-BMC Neurology 2007, 7:27 http://www.biomedcentral.com/1471-2377/7/27
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Table 1: Methodological aspects of all included trials.
Author Number 
of 
patients 
(exclusiv
e 
controls) 
(1)
Study 
methodol
ogy (2)
Patiënt 
selection 
conseque
tive
Golden 
standard 
(3)
Clinical 
daignosti
c criteria 
clearly 
described
?
Minimal 
duration 
follow-up 
after scan 
(month)
Radiotrac
er: pre- 
or 
postsyna
ptic or 
both
Name of 
radiotrac
er (4)
SPECT 
judged 
visually, 
template 
or drawn 
(5)
Part of 
striatum 
judged 
(6)
Cut-off 
point of 2 
sd's taken 
by the 
authors?
Drug 
stopped 
appropria
te before 
SPECT? 
(7)
SPECT 
judged 
blindly 
for 
clinical 
diagnoses
?
Asenbau
m '98
61 II, III - cc yes - pre beta m striatum 2sd yes yes
Benamer 
'00
185 II - cc yes - pre fpcit t striatum - yes yes
Booij '01 20 I - cf yes 24 pre fpcit t striatum 2sd - yes
Buck '95 23 II - cc yes - post ibf t striatum 2sd - -
Eerola 
'05
135 I yes cf yes 24 pre beta m striatum - yes -
Gerschla
ger '02
33 II - cc yes - pre beta m striatum - yes -
Haapanie
mi '01
29 III - cf yes 24 pre beta t striatum - yes yes
Huang 
'01
34 III - cc yes - pre beta m putamen - yes -
Kim '02 31 II - cc yes - both beta/ibf t c-
putamen
-y e s y e s
Laere V 
'04
62 III yes . - . pre fp/tr t c-
putamen
-y e s-
Lee '99 26 II - cc yes - pre ipt m striatum - yes -
Lokkegaa
rd '02
72 I yes cf yes 14 pre beta t striatum - - yes
Lu '04 85 II - cc yes - pre trodat t c-
putamen
-- y e s
Messa '98 18 II - cc yes - pre beta m c-pc - - -
Muller 
'98
24 III - dd yes - pre beta m striatum - yes yes
Oertel 
'93
67 II - fd - 3 post ibzm t striatum 2sd yes -
Oyanagi 
'02
13 II - cc yes - post ibf t striatum - yes -
Pirker '97 19 II - cc yes - post epide m striatum - yes -
Pirker '00 78 II - cc yes - pre beta m striatum - yes -
Pirker '02 51 II - cc yes - pre beta m striatum - yes yes
Plotkin 
'05
57 II yes cc yes - both fp/ibzm t putamen - yes yes
Rooyen v 
'93
21 II - cc - - posr ibzm m striatum - yes -
Schelvsky 
'93
44 II yes dd - - post ibzm t striatum - - -
Schwarz 
'98
65 I - fd yes 24 post ibzm t striatum 2sd yes yes
Schwarz 
'94
20 II - cc - - post ibzm t striatum - - -
Schwarz 
'00
28 III - dd yes - pre ipt t striatum - - -
Schwarz 
'97
55 I - fd - 24 post ibzm t striatum 2sd - yes
Schwarz 
'93
62 I yes fd - 4 post ibzm m striatum 2sd yes yes
Seppi '04 32 II yes cc yes - post ibzm m striatum 2sd yes -
Stoffers 
'05
70 I - cf yes 36 pre beta t c-pc 2sd yes -
Tatsch 
'91
42 II - cc - - post ibzm t striatum 2sd yes -
Vlaar '06 147 I yes cf yes 3 both fp/ibzm t putamen 2sd yes yes
- means "no" or information not clearly mentioned by the authors
1) Number of patients of particular studied included in meta-analysis. Healthy controls and patients with diseases not relevant or inconclusive diagnosis for this study are not 
counted.
2) Study methodology
I = patients with diagnostic uncertainty. Diagnostic accuracy of SPECT was determined with a surrogate gold standard
II = cross sectional study of already diagnosed patient categories
III = early PD vs. normalcy
3) cf = clinical criteria after follow-up
cc = clinical criteria without follow-up
dd = effect dopaminergic drugs or apomorphine test
fd = clinical criteria after follow-up & effect dopaminergic drugs or apomorphine test
4) beta = Iodine-123-beta-CIT (beta-CIT), fpcit = Iodine-123-Ioflupane (FP-CIT), tr = Iodine-123-IPT and 99mCT-TRODAT-1.
ibzm = 123I-iodobenzamide (IBZM), ibf = Iodine-123-Iodobenzofuran (IBF), epide = Iodine-123-epidepride.
5) t = region of interest determined with template
m = region of interest manually encircled
6) bg = basale ganglia or striatum, put = putamen, cp = contralateral putamen, cpc = contralateral putamen/caudate ratio
7) Yes if: drugs with interference with radiotracer were stopped appropriately or if the subjects did not use dopaminergic drugs at the moment of the spect.
(-) if this information was not given or if dopaminergic drugs seemed not to be stopped appropriately.BMC Neurology 2007, 7:27 http://www.biomedcentral.com/1471-2377/7/27
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sonism [34,35], and 3 included patients with inconclusive
parkinsonism or with a questionable effect of anti-parkin-
sonian medication [28,36,37]. Two of the 7 follow-up
studies were retrospective: Lokkegaard and colleagues ret-
rospectively investigated 90 consecutive patients referred
for Beta-CIT SPECT for various reasons, and a non-treat-
ing neurologist obtained the final diagnosis from the clin-
ical records of the patients [38]. Stoffers et al
retrospectively analysed the SPECT scans of 72 patients
with an initial diagnosis of PD, who were then re-diag-
nosed after various intervals [39]. The demographic and
methodological characteristics of all included studies are
visible in Table 1. The absolute numbers of the 2 × 2 tables
of all included trials are shown in Table 2.
Results of the pooled study data analysis
We recalculated the diagnostic power of SPECT for the fol-
lowing clinical problems: 1. diagnosis of PD in an early
phase vs. normalcy; 2 diagnostic differentiation between
PD and ET; 3. diagnostic differentiation between PD and
vascular parkinsonism; 4. diagnostic differentiation
between PD and Atypical Parkinsonian Syndromes (APS)
consisting of MSA and PSP.
1. Diagnosis of PD in an early phase vs. normalcy
Pooled data from selected studies [33,40-44] were used to
calculate the diagnostic accuracy of SPECT to differentiate
between PD and normalcy. All six cross-sectionals (utilis-
ing presynaptic tracers) with patients with known PD in
an early stage (Hoehn & Yahr score of 2 or lesser) had a
specificity of 100%. However sensitivity varied from 8%
to 100%. The pooled odds ratio with a 95%CI was 60 (13
– 277). See also Figure 1.
2. Diagnostic differentiation between PD and essential tremor (ET)
Data from selected studies [33,36,38,45-48] and our own
clinical follow-up study [28] were pooled and pooled
odds ratios for diagnostic power of SPECT were calculated
as described.
For presynaptic radiotracers the pooled odds ratio with
95%CI of the 8 studies together was 210 (79–563). See
also figure 2. All studies scored high sensitivity and specif-
icity.
For calculation of these odds ratios in studies with posts-
ynaptic radiotracers we found 2 studies: one cross-sec-
tional study (sensitivity 100%, specificity of 0%) and our
own follow-up study (sensitivity 60%, specificity 46%).
The pooled odds ratio with 95%CI was 2 (0.4–5). [28,46]
Two studies compared the diagnostic accuracy of the treat-
ing physician with the SPECT in its capacity to delineate
PD from ET [28,38]. Clinical diagnosis in these trials
reached a sensitivity of respectively 76% and 87% and a
specificity of 50% and 80%. The odds ratio with 95%CI of
the two studies together is 9 (3–28).
3. Diagnostic differentiation between PD and vascular parkinsonism 
(VP)
Pooled data from selected studies were used to calculate
the diagnostic accuracy of SPECT to differentiate between
PD and vascular parkinsonism (VP) [28,36,38,47,49].
Patients with PD vs ET Figure 2
Patients with PD vs ET. Presynaptic radiotracer [36, 38, 45-
48, 84]. * = follow-up trial.
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Table 2: Two by two tables for all included trials
True positive False negative True negative False positive
Early PD vs normalcy
Presynaptic
Asenbaum 23 6 30 0
Haapanimie 16 13 21 0
Huang 32 2 17 0
Muller 14 10 15 0
Schwarz '00 28 0 9 0
V. Laere (tracer FP-CIT) 15 24 10 0
V. Laere (tracer: TRODAT) 3 34 10 0
PD vs ET
Presynaptic
Booij '00 7 1 5 0
B e n a m e r  ' 0 0 1 2 7 32 52
Plotkin '05 24 1 11 0
Eerola '05 92 0 16 0
Vlaar '06 90 22 20 1
Lokkegaard '02 44 1 8 0
Asenbaum '98 23 6 32 0
Lee '99 10 1 12 3
Postsynaptic
Vlaar '06 48 33 6 7
Plotkin '05 25 0 0 11
PD vs VP
Presynaptic
Vlaar '06 90 22 14 0
Booij '00 7 1 4 0
Eerola '05 92 0 11 4
Lokkegaard '02 44 1 3 1
Gerschlager '02 18 2 12 1
Postsynaptic
Vlaar '06 65 16 8 4
PD vs APS
Presynaptic
Booij '00 7 1 1 2
Benamer '00 127 3 1 27
Plotkin '05 24 1 3 18
Eerola '05 92 0 1 11
Stoffers '05 30 32 2 6
Lokkegaard '02 44 1 2 13
Kim '02 18 0 1 12
Lu '04 36 0 6 43
Messa '98 13 0 0 5
Pirker '02 26 10 3 7
Vlaar '06 90 22 4 13
postsynaptic
Schwarz '93 45 2 9 6
Schwarz '97 30 4 8 1
Schwarz '98 53 5 5 2
Buck '95 17 0 3 3
Kim '02 18 0 5 8
Oertel '93 49 12 6 0
Oyanagu '02 7 0 2 4
Pirker '97 9 0 0 10
Plotkin '05 25 0 9 12
Schwarz '94 19 0 1 1
Seppi '04 12 5 13 2
Tatsch '91 18 0 20 4
Schelovsky '93 30 0 8 6
Vlaar '06 65 16 16 10
MSA vs PSP
Presynaptic
Vlaar '06 19 0 1 9
Plotkin '05 7 0 1 5
Pirker 7 2 2 4
Pirker 18 0 1 9
Kim '02 11 2 1 7
Benamer '00 4 1 0 2
Postsynaptic
Buck '95 5 2 6 0
Kim '02 1 1 2 2
Plotkin '05 7 6 6 2
Vlaar'06 10 4 3 6
v. Royen '93 13 4 1 3
* In the statistic analyses +0.5 was taken for the zeroes in the 2 × 2 table.BMC Neurology 2007, 7:27 http://www.biomedcentral.com/1471-2377/7/27
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Using presynaptic radiotracers the 5 studies all scored
high sensitivity and specificity for SPECT to differentiate
between PD and VP. The pooled odds ratio with 95%CI of
all five studies together is 105 (32 – 348). See also figure 3.
We were not able to find any trials except our own trial
with postsynaptic tracers aimed at this diagnostic prob-
lem. We found a sensitivity of 80%, specificity of 67% and
an odds ratio of 95%CI of 8 (2 – 30).
Lokkegaard et al. and we mentioned the diagnostic accu-
racy of the clinician to differentiate PD from VP and found
a sensitivity of respectively 87% and 76% and a specificity
of respectively 0% and 63% with a odds ratio 95%CI of 3
(0.5–18) [28,38].
4. Diagnostic differentiation between PD and APS (MSA & PSP)
Pooled data from selected studies were used to calculate
the diagnostic accuracy of SPECT to differentiate between
PD and APS [18,28,30,34-39,46-48,50-59].
When using presynaptic tracers all trials scored moderate
to high sensitivity, but with a low specificity. Combining
all 11 trials the mean odds ratio with 95% CI for the pre-
synaptic tracer to differentiate between PD and the two
APS was 2 (1 – 4). See Figure 4.
When using postsynaptic tracers the 14 trial scored
together a pooled odds ratio 95% CI of 19 (9–36). See Fig-
ure 5.
Four follow-up studies compared the diagnostic accuracy
of the treating physician with the SPECT in its capacity to
delineate PD from the two APS. Clinical diagnosis in these
trials reached a high sensitivity, but a low specificity. The
pooled odds ratio 95% CI was 9 (2 – 34). See Figure 6.
The diagnostic accuracy of SPECT to differentiate MSA
from PSP was low for both the presynaptic and postsynap-
tic radiotracers. With presynaptic racers sensitivity of the 6
trials was extremely high (78 – 100%), however specificity
was low (0–33%). The 5 studies with postsynaptic tracers
scored moderate sensitivity (50 – 71%) and specificity (25
– 100%).
The pooled odds ratio with 95% CI was 2 (0.6 – 7) for the
presynaptic tracers and 2 (0.8 – 6) for the postsynaptic
tracers [28,46,48,50,52,56,60,61].
Discussion
To our knowledge this is the first meta-analysis of the lit-
erature on the diagnostic value of SPECT in patients with
parkinsonian syndromes. Before discussing the actual
results we would like to point out some methodological
problems.
We were very strict in including studies. To compare the
results from selected studies we defined positive tests as
values equal with or exceeding two standard deviations
below healthy controls. When authors defined their posi-
tive results otherwise, we recalculated these, where possi-
ble. However, as many studies did not include raw data,
we had to reject these, as we were then not able to (re)cal-
culate the absolute numbers of true positive, false nega-
tive, true negative, and false positives with a cut-off point
of two standard deviations.
We dichotomised the radiotracers utilised into two
groups: presynaptic and postsynaptic tracers. By doing
this we assumed that all tracers in one group have a simi-
lar reliability. This seems to be reasonable for beta-CIT
and FP-CIT, especially when the SPECT of the parkinso-
nian patient is expressed as a percentage of the binding
ratios found in healthy controls [62,63].
Besides the use of different equipment, comparison
between studies is also hampered by the different meth-
ods that investigators use to calculate the tracer binding.
In some studies the striatum was encircled manually and
others used predefined templates. The striatum was
judged visually (compatible or not compatible with PD)
or fully automated quantitatively by others. Finally, and
possibly the greatest confounding variable: in some stud-
ies the SPECT results are judged by investigators unaware
of the clinical records, but in more than half of the studies
blinding of the investigator is not mentioned.
Another methodological shortcoming in our meta-analy-
sis is the great variability in clinical criteria used to classify
patients; many authors do not even mention these. A
major issue here is that most studies use clearly-defined
later-stage patients that are obviously not representative
Diagnostic differentiation of patients with PD versus VP Figure 3
Diagnostic differentiation of patients with PD versus VP. Pre-
synaptic tracer. [28, 36, 38, 47, 49]. * = follow-up trial.
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for the diagnostic problem that one wants to solve with a
SPECT. We thus limited our analysis to those studies that
addressed the diagnostic accuracy in clinically relevant sit-
uations: early PD, follow-up studies and studies with
known parkinsonian diseases. All the measures men-
tioned above were taken to minimise heterogeneity,
which was actually shown to be minimal as calculated by
the I2 statistic [27]. Despite this, interpreting of the results
should be done with caution, as postsynaptic tracer bind-
ing in APS can be normal in an early stage of disease with
a decrease later on [64]. Finally, strict age-matching is not
done in all studies, but is mandatory as tracer binding in
general decreases with age [65-67].
These methodological problems do, however, allow one
important conclusion to start with: as we derived only 32
papers suitable from a starting number of 185, there is a
paucity of methodologically sound and clinically relevant
papers on this subject. Below we would like to discuss our
results according to the predefined clinically relevant situ-
ations.
Diagnosis of PD in an early phase vs. normalcy
Our meta-analysis confirms the general opinion that
SPECT is relatively accurate to differentiate between
patients with PD in an early stage and healthy controls.
The difference in sensitivity between trials can not be
explained solely by different radiotracer usage. Especially
the difference with the two studies using TRODAT is obvi-
ous [41,43]. An explanation may be that the use of a tem-
plate vs. hand-circling of the striatum leads to lower
diagnostic specificities [40,42,43]. Other possible expla-
nations for the lower sensitivity scores in the study of van
Laere et al are their consecutive inclusion of patients and
their clinic being a tertiary referral centre [43].
Schwarz and Asenbaum were the only two authors who
used two standard deviations below the normal controls
as cut-off [33,42]. In the other four studies we recalculated
the absolute numbers of true positive, false negative etc.
by ourselves, [40,41,43,44] which led in all 4 studies to
lower numbers for diagnostic accuracy. Apart from this
different cut-off point, higher sensitivity figures in several
large trials (normal SPECT scans in 5–10% of clinically
definitive PD patients) are probably explained by the dis-
ease stage of the patients [68-70].
Asenbaum's, Haapaniemi's and Muller's were the only
studies which mentioned blinding of the investigators
[33,40,44]. It is perhaps not surprising that these authors
Diagnostic differentiation between PD and APS (MSA & PSP) Figure 4
Diagnostic differentiation between PD and APS (MSA & PSP). Presynaptic radiotracer. [28, 30, 36, 38, 39, 46-48, 50-52]. * fol-
low-up trial. # The pooled odds ratio after excluding the study of Messa '98 (sensitivity 100%, specificity 0%) remains 
unchanged.
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found lower numbers for diagnostic accuracy than Huang
and Schwarz (See fig. 1) [41,42].
Diagnosis of PD versus ET
The results of our meta-analysis confirm the general opin-
ion that SPECT with presynaptic tracers is highly accurate
to differentiate between patients with PD and ET. Lee et al.
scored lowest specificity. A possible explanation is that
they included not only patients with ET but as well
patients with isolated postural tremor and postural in
combination with resting tremor [45].
Diagnostic differentiation between patients with PD versus 
VP
According to the results of the meta-analysis we conclude
that presynaptic SPECT scans can accurately differentiate
between patients with PD and VP. The specificity, how-
ever, is only moderate in the studies of Lokkegaard and
Eerola [38,47]. VP is a somewhat controversial clinical
concept and the differences found in the studies we ana-
lysed probably reflect the variability in clinical definition.
Whereas Lokkegaard et al., Gerschlager et al., and Eerola
et al. [38,49] used strict inclusion criteria, Booij et al. did
not [36,47]. This point is illustrated in the paper by Lober-
boym et al, who investigated 20 patients with VP with FP-
CIT SPECT. Nine had a normal presynaptic SPECT scan
but 11 had decreased striatal tracer binding. All nine
patients with normal presynaptic SPECT scan had no reac-
tion on levodopa treatment, however 5 of the 11 with
decreased striatal FP-CIT binding did have [71]. Although
SPECT with presynaptic tracers scored high accuracy in
differentiation between PD and VP, conventional tech-
niques like CT and MRI may still be necessary as addi-
tional diagnostic tools.
Diagnostic differentiation between patients with PD versus 
APS
This meta-analysis confirmed the generally accepted view
that presynaptic tracers cannot distinguish between PD
and APS. However, we also found that postsynaptic
SPECT is not very good at this. A negative postsynaptic
SPECT scan does not exclude APS. The positive predictive
value of abnormal postsynaptic SPECT for the diagnosis
of APS is high, making a reduced postsynaptic radiotracer
binding likely to exclude a diagnosis of PD. However,
patients with PD in our meta-analysis do show loss of
dopamine-receptor binding. Studies which used IBZM
scored higher accuracy than studies with IBF or Epide-
pride [50,53,56,59]. If the trials are excluded which used
other tracers than IBZM the mean 95%CI odds ratio only
increased to 21 (11–44).
Diagnostic differentiation of patients with PD vs. APS (MSA &  PSP) Figure 6
Diagnostic differentiation of patients with PD vs. APS (MSA & 
PSP). Doctors Prediction [28, 34, 38, 39]. * follow-up trial. # 
The pooled odds ratio (95%CI) after excluding the studies 
with a sensitivity of 100% and a specificity of 0% (Stoffers '05 
and Schwarz '98) did not change significantly: 6 (1–40). Both 
trials diagnosed at the beginning of the follow-up all patients 
as having PD.
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Diagnostic differentiation of patient with PD vs. APS (MSA &  PSP) Figure 5
Diagnostic differentiation of patient with PD vs. APS (MSA & 
PSP). Postsynaptic radiotracers [18, 28, 34, 35, 37, 46, 50, 53-
59]. * follow-up trial. # The pooled odds ratio (95%CI) after 
excluding the study of Pirker '97 (sensitivity 100%, specificity 
0%) did not change significantly: 19 (10–33). Schwarz 1993. 
this trial can be seen as follow-up trial (long-term l-dopa is 
golden standard) but also as a cross-sectional trial. In the last 
case the results will be different (sensitivity = 79%, specificity 
= 100%). Schwarz 1997: We took signs (in) compatible with 
PD as golden standard. If taken long-term l-dopa as golden 
standard sensitivity is 100% and specificity is 67%. Schwarz 
1998: We took signs (in) compatible with PD taken as golden 
standard, if taken long-term-l-dopa as golden standard sensi-
tivity is 100% and specificity is 50%.
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Some studies, excluded for this meta-analysis, found
excellent accuracy for the postsynaptic tracer to differenti-
ate between PD and APS [19,64,72-77]. Schulz et al, who
investigated 32 MSA patients, found similar results as in
our meta-analysis: only a significant loss in 63% of the
patients using IBZM-SPECT with two standard deviations
under controls (PD patients) as cut-off point [78]. Results
of the studies by Berding et al [79], and Bettin et al [80],
are in line with these.
Possible explanations for the difference in results may be
difference in cut-off points (many authors use only one
SD below healthy controls), and the use of special tech-
niques claimed by some to enhance diagnostic accuracy,
e.g. asymmetric indices, caudate/putamen atio, presynap-
tic/postsynaptic ratio of tracer binding, speed of decline in
follow-up [30,36,76,81,82]. One other explanation of the
low discriminating value of postsynaptic SPECT imaging
is the reversible down regulation of dopamine receptors
by dopaminergic drugs [83]. If the drugs are not stopped
appropriately, the scan result can be false positive. In our
meta-analysis we found 9 studies where potentially inter-
fering medication was not discontinued appropriately or
these did even not mention whether this medication was
discontinued (and if, for how long) before the scan.
Conclusion
There is a paucity of methodologically sound and clini-
cally relevant papers on the diagnostic accuracy of SPECT
in parkinsonian syndromes. Our meta-analysis confirms
the general opinion that SPECT is relatively accurate to
differentiate between patients with PD in an early stage
and healthy controls. We were also able to confirm the
general opinion that SPECT with presynaptic tracers is
highly accurate to differentiate between patients with PD
and ET. Although SPECT with presynaptic tracers scored
high accuracy in differentiation between PD and VP, con-
ventional techniques like CT and MRI may still be neces-
sary as additional diagnostic tools. This meta-analysis
confirmed the generally accepted view that presynaptic
tracers cannot distinguish between PD and APS. However,
we also found that SPECT with postsynaptic tracers is not
very good at this.
Abbreviations
Beta-CIT 123I-Iodine-beta-CIT (presynaptic radiotracer)
CI confidence interval
CT computer tomography
DIP drug induced parkinsonism
ET essential tremor
FP-CIT 123I-ioflupane (presynaptic radiotracer)
IBF 123I-idiobenzofuran (postsynaptic radiotracer)
IBZM 123I-iodobenzamide (postsynaptic radiotracer)
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MSA multiple system atrophy
NPV negative predictive value
OR odds ratio
PET positron emission tomography
PPV positive predictive value
PSP progressive supranuclear palsy
SD standard deviation
SPECT single photon emission computer tomography
TRODAT 99mCT-TRODAT-1 (presynaptic radiotracer)
VP vascular parkinsonism
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